» Articles » PMID: 22371341

Mastoidectomy Cavity Obliteration with Bioactive Glass: a Pilot Study

Overview
Publisher Wiley
Date 2012 Feb 29
PMID 22371341
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To show that mastoid cavities with continuous infections and cleaning problems can be obliterated with bioactive glass (BG) and to present results of a pilot study for 16 operations on adults.

Study Design: Case series with planned data collection.

Setting: Päijät-Häme Central Hospital, Finland-a single ear, nose, and throat (ENT) hospital department serving a population of 216,000.

Subjects And Methods: Fourteen patients had a large open radical cavity with recurrent infections. Two ears had discharge and pain after simple mastoidectomy. A re-mastoidectomy included support of the cavity skin and obliteration with BG. The mean follow-up time was 2.2 years.

Results: All ears became dry. One reoperation was needed as the fascia support to the ear canal (EC) skin was too weak, and part of the BG leaked into the EC. The ear stayed dry, and the missing BG was replaced in a reoperation. A slightly short musculoperiosteal flap supported the EC skin in 1 ear. A minor amount of BG leaked into the EC. The ear stayed dry. The aim was an ample ear canal. One ear was overfilled and required meatoplasty. Simple mastoid cavities were isolated from the middle ear and become asymptomatic.

Conclusions: In this pilot study, BG works safely and with success as an obliteration material in problematic open radical cavities. Bioactive glass seems to tolerate chronic infection in the mastoid and prevent postoperative infections.

Citing Articles

Borosilicate bioactive glass synergizing low-dose antibiotic loaded implants to combat bacteria through ATP disruption and oxidative stress to sequentially achieve osseointegration.

Fan M, Ren Y, Zhu Y, Zhang H, Li S, Liu C Bioact Mater. 2024; 44:184-204.

PMID: 39502840 PMC: 11535878. DOI: 10.1016/j.bioactmat.2024.10.009.


Heterologous Materials Are Really Better than Autologous in Tympanoplasty Mastoid Obliteration? A Systematic Review with Meta-Analysis.

Viberti F, Monciatti G, Donniacuo A, Ferretti F, Salerni L, De Vito A J Int Adv Otol. 2024; 20(5):439-449.

PMID: 39390967 PMC: 11562477. DOI: 10.5152/iao.2024.241262.


Safety and Effectiveness of Bone Allografts for Mastoid Obliteration After Mastoidectomy: A Pilot Study.

Kim W, Park C, Sim S, Hong T, Park S, Heo K J Audiol Otol. 2024; 28(3):221-227.

PMID: 38946329 PMC: 11273184. DOI: 10.7874/jao.2023.00367.


Antibiotics in mastoid and epitympanic obliteration with S53P4 bioactive glass: A retrospective study.

Alciato L, Bernardeschi D, Pourcher V, Mkrtchyan N, Tankere F, Sterkers O Laryngoscope Investig Otolaryngol. 2022; 7(5):1584-1594.

PMID: 36258865 PMC: 9575089. DOI: 10.1002/lio2.923.


Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?.

Cals F, van der Toom H, Metselaar R, van Linge A, van der Schroeff M, Pauw R J Otol. 2022; 17(1):25-30.

PMID: 35140756 PMC: 8811380. DOI: 10.1016/j.joto.2021.10.001.